Chemotherapy and radiotherapy for the removal of the prostate gland can prevent cancer recurrence

Researchers at Oregon Health & Science University Cancer Institute Knight and Portland Veterans Affairs Medical Center, found a combination of radiotherapy and chemotherapy given before removal of the prostate is safe and may have the potential to reduce cancer recurrence and survival of patients improve. Their results were this week at the 51st Annual Meeting of the American Society of Therapeutic Radiology and Oncology in Chicago.

"Occur men Achieved aggressive cancer of the prostate, such as white standard radiation treatment or surgery is often not enough to completely eliminate the cancer treatment site. In these tumors, again, they are often fatal, "said the report Mark Garzotto, MD, associate director INVESTIGATOR and professor of urology and radiation medicine OHSU Knight Cancer Institute and head of urologic oncology at Portland Veterans Affairs Medical Center.

Previous clinical trials evaluating the effect of two, or hormone therapy, chemotherapy before surgery showed little or no advantage over the prostate, only the kidnapping. New approaches are needed if we are to make progress in this disease, "one said Dr. Garzotto.

The use of multimodal therapy resulted - the association and radio-surgery Chemotherapy - Prostate In better results in a number of cancers, but has not yet been wrote in cancer.

This study sought to find out if radiotherapy and chemotherapy (docetaxel) Before the surgery is feasible, safe and could ultimately prevent, manage the recurrence of cancer. Responding to questions at CES Garzotto and his colleagues have developed a treatment regimen, administered in Which Radiation and docetaxel before prostatectomy Ensemble.

Twelve participants were eligible for the study between April 2006 and are trademarks of March 2008th The men were paid and the intensity of the radiation dose docetaxel Crescent Five weeks of pay, prostate Followed by surgical removal of the .

Participants tolerated the treatment well and had the surgery without major complications, with a potential interest in this study to be submitted. Especially when there were no lesions, rectal ureter, or the formation of blood clot in the legs. Examination of tumor tissue after surgery, the margins of cancer, suppression of evidence A comprehensive review of all cancers, one was found in 75 percent of patients is more than the pupil could clean s' wait. In addition, the prostate specific antigen or PSA, an indicator of recurrent prostate cancer, detected after treatment in all patients.

The combination of our study, since the first clinical trial for prostate cancer on radiation therapy, chemotherapy and surgery as treatment of the association before prostate surgery May require cure rates than traditional approaches with fewer side effects ", a declare Arthur Hung, MD, Co-Investigator and Assistant Professor of Nuclear Medicine OHSU Cancer Institute Knight.

The researchers found that the combination of chemotherapy and radiotherapy is feasible and safe, and potentially cancer recurrence in this population at high risk be reduced. In addition, they say, the development of this approach the door of the study, other drugs opens in combination with radiotherapy.